New Antibiotics for Resistant Infections: What Happens After Approval?
Annals of Internal Medicine · 2024
DOI: 10.7326/m24-0192 ↗Kurz gefasst
Editorial in der Zeitschrift Annals of Internal Medicine, 2024. Verfasst von Jessica Howard-Anderson und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Drug Approval, United States Food and Drug Administration. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.
- Tufts University School of Medicine and Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts.
Zitieren
APA
Howard-Anderson, J., & Boucher, H. W. (2024). New Antibiotics for Resistant Infections: What Happens After Approval?. Annals of Internal Medicine. https://doi.org/10.7326/m24-0192
Vancouver
Howard-Anderson J, Boucher HW. New Antibiotics for Resistant Infections: What Happens After Approval?. Annals of Internal Medicine. 2024. doi:10.7326/m24-0192
BibTeX
@article{HowardAnderson2024,
author = {Howard-Anderson, Jessica and Boucher, Helen W},
title = {New Antibiotics for Resistant Infections: What Happens After Approval?},
journal = {Annals of Internal Medicine},
year = {2024},
doi = {10.7326/m24-0192}
}
EUVIMED